Výsledky vyhledávání - "Martin B. Cohen"

Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: A randomized trial

Autor: Michael R. Rudnick, Stanley Goldfarb, Lewis Wexler, Philip A. Ludbrook, Mary J. Murphy, Elkan F. Halpern, James A. Hill, Michael Winniford, Martin B. Cohen, Douglas B. VanFossen, null for the Iohexol Cooperative Study

Publikováno v: Kidney International. 47(1):254-261

Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: A randomized trial. The incidence of nephrotoxicity occurring with the nonionic contrast agent, iohexol, and the ionic contrast agent, meglumine/sodium diatrizoate, was compared in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b20de4f93f93dcb4d4de75a0ff5cfa07

Zobrazit plný text záznamu

Iodixanol, a new isosmotic nonionic contrast agent compared with iohexol in cardiac angiography

Autor: James A. Hill, Martin B. Cohen, G.B. John Mancini, William H. Kou, Michael K. Mansour, Harvey Fountaine, Jeffrey A. Brinker

Publikováno v: The American Journal of Cardiology. 74:57-63

Iodixanol, a new ratio 6 nonionic iodinated contrast agent with an osmolality equal to serum, was compared with iohexol in a randomized, double-blind, parallel study. Two hundred patients undergoing elective diagnostic cardiac angiography were random

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b6d2167b666fb7c593f889fe2fd45d1
https://doi.org/10.1016/0002-9149(94)90492-8

Zobrazit plný text záznamu

Multicenter trial of ionic versus nonionic contrast media for cardiac angiography

Autor: Mary J. Murphy, Martin B. Cohen, Michael D. Winniford, Elkan F. Halpern, Stanley Goldfarb, Michael R. Rudnick, James A. Hill, Lewis Wexler, Douglas B. Van Fossen, Philip A. Ludbrook

Publikováno v: The American Journal of Cardiology. 72:770-775

Contrast agents used for cardiac angiography are different in regard to ionicity, osmolality and physiologic effects. The nonionic contrast media have been shown to have less toxic effects and a better safety profile than do higher osmolar agents. To

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::07e56c2c0d3ec843acefd2e7d034ef89
https://doi.org/10.1016/0002-9149(93)91061-l

Zobrazit plný text záznamu

Tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty: One-year TIMI phase II pilot results

Autor: Morton J. Kern, Rachel E. Solomon, Michel Vandormael, Nicholas A. Ruocco, Martin B. Cohen, Eugene Braunwald, Bruce Thompson, Bernard R. Chaitman, Timi Investigators

Publikováno v: American Heart Journal. 119:213-223

The TIMI phase II pilot study enrolled 288 patients with acute myocardial infarction who weretreated with recombinant tissue plasminogen activator (rt-PA) within 4 hours of symptom onset and who were assigned to coronary angioplasty of the infarct-re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8af6354104392e88af839054453809dc
https://doi.org/10.1016/s0002-8703(05)80007-9

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání